Corporate Banner
Satellite Banner
Mass Spectrometry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Flagship Partners with Expression Pathology to Combine Tissue Proteomics and Digital Pathology

Published: Sunday, December 12, 2010
Last Updated: Sunday, December 12, 2010
Bookmark and Share
Two leading companies offer clients integrated services for digital pathology and quantitative mass-spec based tissue proteomics.

Expression Pathology, the leading provider of FFPE tissue-based proteomics, and Flagship Biosciences, the leading digital pathology services firm, announce a service partnership that enables tissue translational biomarker development, validation and application in support of drug development.

Many pharmaceutical, biotech and academic clinical research organizations require robust targeted assays to translate and validate their biomarker discovery efforts with respect to protein expression in tissue. Customers of Expression Pathology and Flagship can now leverage expertise with tissue biomarkers to quickly develop quantitative evidence-based assays using the combined know how of mass-spec tissue analysis and digital pathology. Flagship’s pathology expertise to ensure the right tissue or sub anatomic organelle is analyzed combined with Expression Pathology’s expertise in multiplex tissue proteomic assays using FFPE tissue offers comprehensive tissue analysis service to customers.

“Expression Pathology’s unique and proprietary Liquid Tissue® SRM assays for quantitative analyses of proteins in FFPE tissue are opening huge opportunities in personalized medicine to relate those measurements to patient treatment decisions” said Casey Eitner, President and CEO of Expression Pathology Inc.

“Translational and personalized medicine today requires better integration of the enabling technologies these platforms and new generation of service organizations provide,” said John Bloom, a member of Flagship’s Board of Directors and a well-known leader in translational medicine. “This novel partnership is prototypic of what is required to meet the needs of drug development and patient care in this dynamic area of applied biomarker science.”

Expression Pathology Inc. (EPI) is a private biotechnology company leading the development of innovative assays to measure functional tissue proteins in research and diagnostic applications.
Flagship Biosciences LLC is a pathologist-owned contract research organization that delivers quantitative pathology and tissue-based companion diagnostics in drug and device development.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Expression Pathology Obtains Second U.S. Liquid Tissue® Patent
Patent cover methods that increase the range of proteins and protein modifications which can be analyzed using the company’s patented Liquid Tissue® method.
Sunday, April 10, 2011
Expression Pathology Provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development
The Liquid Tissue®-SRM Technology accelerates identification of cancer molecular markers for developing more effective treatments.
Wednesday, January 12, 2011
Expression Pathology provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development
Expression Pathology Inc. announced an agreement with Roche wherein Expression Pathology will provide its Liquid Tissue®-SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.
Tuesday, January 11, 2011
Expression Pathology’s Liquid Tissue Patent Issues in Japan
Patent covers tissue processing methods to enable discovery and accurate measurement of protein biomarkers in standard FFPE tissue by mass spectrometry.
Tuesday, September 28, 2010
Key U.S. Patent Issues on Expression Pathology’s Liquid Tissue® Technology
The patent claims methods to enable protein analysis in FFPE tissue for clinical research and diagnostics.
Wednesday, January 07, 2009
Expression Pathology to Collaborate in $300,000 Alberta Breast Cancer Research
EPI will employ its tissue proteomics technologies to identify protein biomarkers of metastasis.
Tuesday, September 30, 2008
EPI Licenses Harvard’s AQUA™ Peptide Technology
Company licenses the patent rights for mass spectrometry quantitation of proteins in patient tissue.
Wednesday, August 30, 2006
Publication Shows Cancer Biomarker Identification in Formalin-Fixed Tissue
The article describes LC MS/MS mass spectrometry analysis of FFPE prostate cancer tissue.
Thursday, November 10, 2005
Scientific News
Newly Identified Biochemical Pathway Could Be Target for Insulin Control
Researchers at Duke Medicine and the University of Alberta are reporting the identification of a new biochemical pathway to control insulin secretion from islet beta cells in the pancreas, establishing a potential target for insulin control.
Dirty,Crusty Meals Fit for (Long-Dormant) Microbes
Researchers apply the latest analytical techniques to further our understanding of desert biocrusts.
CSI -- On The Metabolite's Trail
Bioinformaticians at the University of Jena make the most efficient search engine for molecular structures available online.
First Complete Structural Study Of A Pegylated Protein
Significant data obtained at NUI Galway reports first crystal structure of a protein modified with a single PEG chain.
Potential Ovarian Cancer Biomarker Isolated
Researchers from North Carolina State University utilized a highly sensitive mass spectrometry analysis to identify and measure difficult-to-detect N-glycan biomarkers associated with ovarian cancers in stages I – IV.
Waters’ Centers of Innovation Program Honors Ohio State University Laboratory
Wysocki-led facility recognized for proteomics, disease research and mass spectrometry excellence.
Protein Aggregation After Heat Shock Is An Organized, Reversible Response
New study finds protein aggregation after heat exposure is a reversible cellular process, not unrecoverable damage from misfolding.
World’s Largest Protein Interaction Map Created
A multinational team of scientists sifted through cells of vastly different organisms – from amoebae to worms to mice to humans – to reveal how proteins fit together to build different cells and bodies.
Evidence of Ancient Life Discovered Deep Below the Seafloor
Ancient rocks harbored microbial life deep below the seafloor, reports a team of scientists from the Woods Hole Oceanographic Institution (WHOI), Virginia Tech, and the University of Bremen.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos